KalVista

FDA
Pharma

KalVista secures rare disease approval following FDA delay

After facing an unexpected regulatory delay last month, KalVista Pharmaceuticals has leapt into the commercial realm.
Fraiser Kansteiner Jul 7, 2025 10:14am
FDA stop sign
Favicon Fierce Biotech

FDA's 'heavy workload' blamed for delaying KalVista's PDUFA date

Jun 16, 2025 4:33am